Corvus Pharmaceuticals

Price & Volume

Track all markets on TradingView

Stats

See more
Open
$5.71
Previous Close
$5.48
Day Range
$5.56-$5.82
52W Range
$1.05-$6.15
Market Cap
$344M
Shares Short
1M

Financials

See more
Revenue (12 Mos)
$0
Revenue Growth (YoY)
0%
Gross Profit (12 Mos)
$0
Diluted EPS
-$0.43

News

See more

Yahoo Finance • 11 months ago

Corvus Pharmaceuticals to Present New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition

Yahoo Finance • 11 months ago

Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to T Cell-Mediated Inflammatory and Immune Diseases

Yahoo Finance • last year

Corvus Pharmaceuticals Confirms Planned Initiation of Soquelitinib (CPI-818) Phase 3 Registrational Clinical Trial in Peripheral T Cell Lymphoma Following Meeting with FDA

Yahoo Finance • last year

Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential Novel Approach to Immunotherapy Based on Inhibition of ITK with Soquelitinib (CPI-818)

About

CEO
Dr. Richard A. Miller M.D.
Address
863 Mitten Road, Burlingame, CA, United States, 94010
Sector
Healthcare
Industry
Biotechnology
Full-Time Employees
28